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Abstract
Background: Hydroxycamptothecin (HCPT) has been shown to have activity against a broad
spectrum of cancers. In order to enhance its tissue-specific delivery and anticancer activity, we
prepared HCPT-loaded nanoparticles made from poly(ethylene glycol)-poly(γ-benzyl-L-glutamate)
(PEG-PBLG), and then studied their release characteristics, pharmacokinetic characteristics, and
anticancer effects. PEG-PBLG nanoparticles incorporating HCPT were prepared by a dialysis
method. Scanning electron microscopy (SEM) was used to observe the shape and diameter of the
nanoparticles. The HCPT release characteristics in vitro were evaluated by ultraviolet
spectrophotometry. A high-performance liquid chromatography (HPLC) detection method for
determining HCPT in rabbit plasma was established. The pharmacokinetic parameters of HCPT/
PEG-PBLG nanoparticles were compared with those of HCPT.
Results:  The HCPT-loaded nanoparticles had a core-shell spherical structure, with a core
diameter of 200 nm and a shell thickness of 30 nm. Drug-loading capacity and drug encapsulation
were 7.5 and 56.8%, respectively. The HCPT release profile was biphasic, with an initial abrupt
release, followed by sustained release. The terminal elimination half-lives (t 1/2 β) of HCPT and
HCPT-loaded nanoparticles were 4.5 and 10.1 h, respectively. Peak concentrations (Cmax) of
HCPT and HCPT-loaded nanoparticles were 2627.8 and 1513.5 µg/L, respectively. The apparent
volumes of distribution of the HCPT and HCPT-loaded nanoparticles were 7.3 and 20.0 L,
respectively. Compared with a blank control group, Lovo cell xenografts or Tca8113 cell
xenografts in HCPT or HCPT-loaded nanoparticle treated groups grew more slowly and the tumor
doubling times were increased. The tumor inhibition effect in the HCPT-loaded nanosphere-
treated group was significantly higher than that of the HCPT-treated group (p < 0.01). Tumor
inhibition in the control group by PEG-PBLG nanoparticles was not observed (p > 0.05).
Conclusion:  Compared to the HCPT- and control-treated groups, the HCPT-loaded
nanoparticle-treated group showed a more sustained release, a longer circulation time, increased
delivery to tissue, and an enhanced anticancer effect. HCPT-loaded nanoparticles appear to change
the pharmacokinetic behavior of HCPT in vivo.
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Background
In recent years, microspheres, liposomes, and biodegrad-
able polymers have been used in site-specific drug delivery
systems [1-3]. Hydrophilic-hydrophobic diblock copoly-
mers exhibit amphiphilic behavior and form micelles
with core-shell architecture. The hydrophobic block forms
the inner core, which acts as a drug incorporation site,
especially for the hydrophobic drugs. The hydrophilic
block forms the hydrated outer shell, which plays a role in
preventing uptake by the reticuloendothelial system
(RES) [2,4]. The predominant characteristics of these
copolymers that have been reported include solubiliza-
tion of hydrophobic drugs, sustained release, selective tar-
geting, and lower interactions with the RES [2,4,5].
Nanoparticles made from poly(γ-benzyl L-glutamate)
(PBLG) and poly(ethylene oxide) (PEG) are hydrophilic-
hydrophobic diblock copolymers which have these pre-
dominant characteristics [6,7]. Thus, this PEG-PBLG
copolymeric carrier may serve as an appropriate vehicle
for drug delivery [6,7].
The anticancer activity of camptothecin (CPT) and its nat-
ural and synthetic analogs has been shown in a broad
spectrum of cancers, including leukemias and cancers of
the liver, stomach, breast, and colon [8-10]. Among natu-
ral CPTs, 10-hydroxycamptothecin (HCPT) has been
shown to be more active and less toxic [8,9,11]; however,
natural HCPT is in a lactone form and is water-insoluble.
One way to improve the solubility of HCPT is to change
the lactone form to the carboxylate form by adding
NaOH. However, this leads to less activity and more
unwanted toxicity [8,9]. At the same time, HCPT has a
short half-life in vivo and poor biodistribution [12].
To improve the solubility of CPT analogs, the lactone
form of the analogs was incorporated into liposomes or
nanoparticles [13-15]. These delivery systems show favo-
rable pharmacokinetics and biodistribution [13-15]. In
the present study, we prepared HCPT-loaded PEG-PBLG
nanoparticles and investigated the in vitro release, phar-
macokinetics, and anticancer effect. Our results showed
that HCPT-loaded nanoparticles changed the pharmacok-
inetic behavior of HCPT in vivo. The HCPT-loaded nano-
particles had a more sustained release, a longer circulation
time, increased delivery to tissue, and an enhanced anti-
cancer effect.
Results
Characteristics of HCPT-loaded nanoparticles
In this study, HCPT-loaded PBLG/PEG nanoparticles were
prepared using dialysis. After analysis by UV spectropho-
tometey, we found that the solution of HCPT in a stand-
ard sample, or the simple mixture of a solution of HCPT
and PBLG/PEG, had high absorbency in the wavelength
range, 326 – 368 nm (Fig. 1A,B). However, the absorb-
ency of the solution of HCPT-loaded PBLG/PEG nanopar-
ticles was greatly decreased (Fig. 1C), representing the
formation of HCPT-loaded PEG-PBLG nanoparticles. On
the basis of absorbency at 326 nm, the drug-loading
capacity and drug encapsulation of HCPT-loaded nano-
particles were 7.5 and 56.8%, respectively.
The morphology of HCPT-loaded nanoparticles (Fig. 1D)
was found to be a core-shell structure that was spherical or
elliptical, with a smooth surface. The hydrophobic central
core, the grayish area inside the bright white ring, was
approximately 200 nm in diameter. The hydrophilic shell,
the bright white ring, was approximately 30 nm in thick-
ness.
Abrupt-sustained release of HCPT-loaded nanoparticles
The standard curve of a HCPT solution was derived from
the following equation: y = 10.7 x + 0.0056 (r = 0.9999).
HCPT release from PEG-PBLG nanoparticles at pHs 6.86
and 9.18 in vitro is shown on Fig. 2. The HCPT release
profile was biphasic, with an initial abrupt release, fol-
lowed by sustained release. Abrupt release occurred at 2 h,
and 1/3 of the loaded HCPT was released by that time.
Then, the release of HCPT entered sustained release fol-
lowing initial abrupt release. After 96 h, 3/5 of the loaded
HCPT was still enveloped in the nanoparticles. In this
release study, HCPT-loaded nanoparticles showed a
quicker release pattern in the more alkaline condition.
Pharmacokinetic characteristics of HCPT-loaded 
nanoparticles
The standard curve for HCPT in rabbit plasma was derived
from the following equation: y = 2.75 x +2.90 (γ >
0.9999), where Y is the concentration (µg/L) and X is the
peak height. The limit of determination was 2 µg/L. The
mean plasma concentrations over time for the free HCPT
and the HCPT-loaded nanoparticles are illustrated in Fig.
3. The HCPT release profile from HCPT-loaded nanopar-
ticles was biphasic with an initial abrupt release, followed
by sustained release. Abrupt release occurred at 1 h and
the peak concentration was 1513.5 µg/L. During the sus-
tained release, the plasma concentration was between 7.4
– 84.7 µg/L. As shown in Table 1, the pharmacokinetics of
HCPT changed after it was loaded into PEG-PBLG nano-
particles. The terminal elimination half-life was longer,
the peak concentration decreased, and the apparent vol-
ume of distribution increased.
Tumor inhibition effect of HCPT-loaded nanoparticles in 
vivo
Tumor-associated swellings were visible in all the mice. As
demonstrated by the tumor growth curve of Lovo (Fig.
4A) and Tca8113 cell xenografts (Fig. 4B), xenograft
growth was fast in the blank and PEG-PBLG control
groups, but significantly depressed in the HCPT- orBMC Biotechnology 2008, 8:46 http://www.biomedcentral.com/1472-6750/8/46
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HCPT/PEG-PBLG-treated groups. As shown in Table 2,
tumor doubling time lengthened with treatment. The
inhibition rate for HCPT alone was between 60 and 70%,
but was greater than 80% for the HCPT-loaded nanopar-
ticles. The tumor volumes of the HCPT and HCPT-loaded
nanoparticle-treated groups were significantly less than
those of the blank and PEG-PBLG control groups (P <
0.01). There was also significantly more tumor inhibition
in the HCPT-loaded nanoparticle treated group than in
the HCPT treated group (P < 0.01). However, there was no
significant difference in tumor inhibition between the two
control groups (P > 0.05). No significant toxicity was
observed in any of the groups.
Discussion
Drug-loaded nanoparticles made from natural and syn-
thetic macromolecular materials that are biocompatible
and biodegradable have been used for controlling the
release of drugs and changing pharmacokinetics and the
targets of drug action [1-3]. Nanoparticles have been used
Characteristics of HCPT-loaded nanoparticles Figure 1
Characteristics of HCPT-loaded nanoparticles. (A-C): UV spectrum of HCPT detected by ultraviolet spectrophotome-
try. At wavelengths of 326 and 368 nm, both the HCPT standard sample (A) and the mixture of HCPT and PBLG/PEG (B) had 
high absorbency, but the absorbency of HCPT-loaded PBLG/PEG nanoparticles (C) was greatly decreased. (D) The morphol-
ogy of HCPT-loaded nanoparticles was found under scanning electron microscopy (× 160 000) to be a core-shell structure, 
spherical or elliptical, with a smooth surface. The hydrophobic central core was a grayish area, approximately 200 nm in diam-
eter. The hydrophilic shell was a bright white ring, approximately 30 nm thick.
Table 1: The pharmacokinetic parameters of HCPT or HCPT-loaded nanoparticles after IV administration at a single dose of 12 mg/kg 
in rabbit
t 1/2 (h) Cmax (µg/L) Tmax(h) Vd(L) AUC(µg · h/L)
HCPT 4.5 2627.8 0 7.3 2459.0
HCPT/PEG-PBLG 10.1 1513.5 1 20 2175.9
T1/2β : terminal elimination half-life; Cmax: peak concentration; Tmax: peak time; AUC: area under the curve ;Vd : apparent volume of distribution.BMC Biotechnology 2008, 8:46 http://www.biomedcentral.com/1472-6750/8/46
Page 4 of 7
(page number not for citation purposes)
to load anticancer drugs to enhance their anticancer effect
and decrease their toxicity [14,15], especially for water-
insoluble drugs. Nanoparticles made from PEG and
PBLG, which are biocompatible and biodegradable mac-
romolecule materials, have been used to load drugs [6,7].
In this study, HCPT-loaded PEG-PBLG nanoparticles were
prepared by dialysis, and the drug loading capacity was
7.5%, which was obviously higher than that of HCPT-
loaded polybutylcyanoacrylate nanoparticles (1.22%)
prepared by the adsorption-enwrapping method [16].
Like many other copolymer nanoparticles [6,7], the shape
of HCPT-loaded nanoparticles was mostly spherical or
ellipsoid. Close observation of SEM photographs revealed
grayish and bright white profiles in the copolymer nano-
particles, which indicated that they are of the core shell
type. The grayish center portion, which was 200 nm in
diameter, was assigned to the core of the hydrophobic
PBLG, and the bright white ring, which was 30 nm in
thickness, was assigned to the shell of the hydrophilic
PEG. Studies have revealed that nanoparticles are not eas-
ily phagocytized by phagocytes when the thickness of the
PEG layer is 10 nm for every 100 nm thickness of micelles
[17]. Thus, the size of the nanoparticles was suitable to
avoid uptake by the RES.
Numerous data have shown that the release of drugs from
nanoparticles is biphasic, with abrupt and sustained
release components [18]. Abrupt release includes release
of the drug adsorbed at the surface of the nanoparticles or
diffused from the polymer matrix. Abrupt release enables
the drug to quickly reach effective blood concentrations.
Sustained release is the release of the drug that was
enwrapped inside the nanoparticles and occurs when the
nanoparticles biodegrade, or diffuse from the polymer
matrix. Sustained release is advantageous to maintain
effective blood concentrations of the drug. In this study,
the release profile of the HCPT-loaded nanoparticles also
consisted of an abrupt release and a sustained release. The
HCPT-loaded nanoparticles also showed a quick release
pattern in the alkaline condition in vitro. This may be
related to the fact that the lactone form of HCPT converts
to the carboxylate form in the alkaline condition and
becomes water-soluble.
HCPT is an inhibitor of topoisomerase I (Topo I). Other
researchers have revealed that only the lactone form of
HCPT can form a stable compound with Topo I and DNA,
which may be responsible for its anticancer effect [8]. The
carboxylate form of HCPT has a low anticancer effect,
high toxicity, and poor stability. Previous pharmacoki-
netic studies with HCPT have indicated that HCPT has a
short half-life, a poor affinity for tissue, and a higher com-
bination rate with plasma protein [12,19]. In this study,
we found the same results. Therefore, to improve the anti-
cancer effect and decrease the toxicity of HCPT, many
researchers have investigated a new preparation of HCPT
[13,15,16]. Williams et al. [15] prepared SN-38- (an active
compound of irinotecan) loaded phospholipid-PEG nan-
oparticles by the solvent-evaporation method, which
enhanced the lactone ring stability in the presence of
human serum albumin and prolonged the existence of the
Release characteristics of HCPT from PEG-PBLG nanoparti- cles in vitro in different buffers Figure 2
Release characteristics of HCPT from PEG-PBLG 
nanoparticles in vitro in different buffers. The HCPT 
release profile was biphasic with an initial abrupt release, fol-
lowed by sustained release. The abrupt release occurred at 2 
h and 1/3 of the loaded-HCPT was released during this 
period. Then, the HCPT entered the sustained release; after 
96 h, 3/5 of the loaded-HCPT was still enwrapped in the nan-
oparticles. In this release study, HCPT-loaded nanoparticles 
also showed a quick release pattern in the alkaline condition.
Table 2: The anticancer effect of HCPT-loaded nanoparticles in the treatment of xenografts
Lovo cells xenograft Tca8113 cells xenograft
TDT (d) IR (%) TV(cm3) TDT (d) IR (%) TV(cm3)
Blank control 3.0 0 4.336 ± 0.485 3.5 0 3.888 ± 0.547
PEG-PBLG 2.9 0 4.206 ± 0.308* 3.6 0 3.944 ± 0.179*
HCPT 4.3 70.0% 1.299 ± 0.082# 4.5 59.8% 1.564 ± 0.286#
HCPT/PEG-PBLG 4.9 83.8% 0.701 ± 0.067#§ 4.9 85.6% 0.559 ± 0.062#§
TDT: tumor doubling time; IR: inhibition rate; TV: tumor volume at day 21 for Lovo cells xenograft or day 34 for Tca8113 cells xenograft
*: compared with blank: P = 0.451 or 0.765(front:Lovo xenograft; the latter:Tca8113 xenograft); #: compared with blank: P = 0.000;
§: Compared with HCPT: P = 0.002 or 0.000(front:Lovo xenograft; the latter:Tca8113 xenograft)BMC Biotechnology 2008, 8:46 http://www.biomedcentral.com/1472-6750/8/46
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active drug (lactone form) and the half-life in vivo. HCPT-
loaded nanoparticles prepared by Zhang [16] were tar-
geted to the liver and had a sustained release effect. In our
study, the pharmacokinetic parameters of HCPT changed
after it was enveloped in the PEG-PBLG nanoparticles.
Compared with HCPT, the pharmacokinetic parameters
for the HCPT/PEG-PBLG nanoparticles had the following
changes: 1) the terminal elimination half-life increased,
2) the peak concentration decreased, and 3) the apparent
volume of distribution increased. These results indicate
that the HCPT-loaded nanoparticles have the following
characteristics: 1) sustained release, 2) prolonged half-life,
and 3) increased affinity to tissue. Therefore, they have the
properties of an ideal new preparation of HCPT. The stud-
ies of Li et al. [7] and Jeong et al. [6] have also shown that
5-fluorouracil- or adriamycin-loaded PEG-PBLG nanopar-
ticles have similar pharmacokinetic characteristics.
HCPT has known clinical efficacy against a variety of solid
tumors in humans [8,9]. In this study, free HCPT inhib-
ited the xenograft growths of colon cancer and oral squa-
mous cell carcinoma, and prolonged the tumor doubling
times. These findings were also demonstrated in our pre-
vious studies [9,20]. Compared with free HCPT, HCPT-
loaded nanoparticles had a higher inhibitory effect on
colon cancer and oral squamous cell carcinoma. Williams
et al. [15] reported a similar result; after treatment with
SN-38-loaded phospholipd-PEG, the anticancer effect
against HT-29 colon xenografts was higher compared to
CPT-11. The higher anticancer effect of HCPT-loaded nan-
oparticles may be due to one or more of the following rea-
sons. First, the HCPT-loaded nanoparticles have sustained
release, a prolonged half-life, and increase the apparent
volume of distribution. These characteristics may increase
the exposure time of the drug to tumor tissues. Second,
the HCPT-loaded nanoparticles stabilize the lactone form
of HCPT, which inhibits the activity of Topo I. The longer
the period of stabilization, the stronger the anticancer
effect. Third, tumor tissue has an abundant blood supply
and tumor cells exhibit higher phagocytotic ability.
Together, these characteristics would make nanoparticles
more likely to enter the tumor cells and would improve
the anticancer effect.
The mean plasma concentration of HCPT after IV adminis- tration of HCPT or HCPT/PEG-PBLG nanospheres at a sin- gle dose of 12 mg/kg Figure 3
The mean plasma concentration of HCPT after IV 
administration of HCPT or HCPT/PEG-PBLG nano-
spheres at a single dose of 12 mg/kg. The HCPT release 
profile from HCPT-loaded nanoparticles showed a biphasic 
with an initial abrupt release, followed by a sustained release. 
The abrupt release occurred at 1 h and the peak concentra-
tion was 1513.5 µg/L. The release then became sustained, 
with a plasma concentration between 84.7 and 7.4 µg/L.
The tumor growth curve of Lovo cell xenografts (4A) or Tca8113 cell xenografts (4B) Figure 4
The tumor growth curve of Lovo cell xenografts (4A) or Tca8113 cell xenografts (4B). Xenografts grew quickly in 
the blank and PEG-PBLG control groups, but growth was significantly slowed in the HCPT- and HCPT/PEG-PBLG-treated 
groups.BMC Biotechnology 2008, 8:46 http://www.biomedcentral.com/1472-6750/8/46
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Conclusion
From this research, we found that PEG-PBLG nanoparti-
cles are useful for the solubilization and sustained release
of HCPT. HCPT-loaded PEG-PBLG nanoparticles
improved the tissue-specific delivery and the anticancer
effect of HCPT by changing the pharmacokinetic behavior
of HCPT in vivo.
Methods
Materials
PEG-PBLG block copolymers were prepared by polymeri-
zation of γ-benzyl L-glutamate N-carboxyanhydride (γ-
BLG NCA) initiated with mono amine-terminated PEG in
a methylene dichloride solution by the method described
previously [7]. HCPT (lactone form) powder (> 98.5%
purity) and HCPT liquid injection were obtained from
Huangshi Lishizhen Pharmaceutical Co. (Hubei, China).
All other reagents were of analytical grade. Human colon
cancer cells (Lovo cell line) or oral squamous carcinoma
cells (Tca8113 cell line) were grown in RPMI 1640
(GIBCO, USA) with 10% fetal calf serum (GIBCO), 100
units/ml penicillin G, and 100 µg/ml streptomycin at
37°C in 5% CO2. New Zealand rabbits (2–3 kg) and SPF
BALB/c nude mice, 6–8 weeks of age (20–30 g) were pur-
chased from the Animal Center of Sun Yat-sen University.
Animal experiments were performed with the permission
of the Animal Ethical Commission of Sun Yat-sen Univer-
sity.
Preparation and identification of HCPT-loaded 
nanoparticles
HCPT-loaded PEG-PBLG nanoparticles were prepared by
dialysis, as described previously [7]. Briefly, PEG-PBLG
diblock copolymer and HCPT (1:1 W/W) were dissolved
in N,N-dimethylformamide (DMF), then dialyzed using a
dialysis bag (molecular cut-off 3500 g/mol; Spectrum
Medical Industries, Inc., Houston, TX) against double-dis-
tilled water for 24 h. The solution inside the dialysis bag
was centrifuged and supernatant (nanoparticles) was fil-
tered through a 0.45 µm filter. A 640 UV spectrophotom-
eter (Beckman) was used to identify the HCPT-loaded
PEG-PBLG nanoparticles at the wavelengths, 200–400
nm. The morphology of nanoparticles was observed using
a scanning electron microscope (SEM, HITACHI-600;
Japan).
Drug-loading capacity and drug encapsulation
HCPT-loaded PEG-PBLG nanoparticles were added into
the dialysis bag, which was placed in DMF. The solution
outside the dialysis bag was stirred at 37°C for 3 h and
then the drug concentration was measured using a UV
spectrophotometer at 326 nm. Absorbency of the solution
(A) was used to calculate the drug-loading capacity and
drug encapsulation according to the following formulae:
drug loading capacity = MHCPT/MHCPT/PEG-PBLG and drug
encapsulation = MHCPT/M drug devoted, where MHCPT was the
drug content of the detected solution (MHCPT = DHCPT × V,
DHCPT = Asample/Astandard) × Dstandard, D: concentration, V:
volume), MHCPT/PEG-PBLG was the quantity of the detected
solution of HCPT/PEG-PBLG nanoparticles, and Mdrug
devoted was the initial quantity of HCPT.
In vitro release
HCPT-loaded nanoparticles were added to a dialysis bag
and then introduced into a vial with PBS at different pHs
(6.86 and 9.18). The medium was stirred at 94 ± 4 revolu-
tions/min at 37°C. At the indicated time intervals
(observed until 96 h), the medium was removed and
replaced with fresh PBS. The absorbency of samples of
these replaced media was detected by an UV spectropho-
tometer at 326 nm. The released HCPT in these replaced
media at different time intervals was calculated from the
standard curve, which was set up in the same way. Then,
the release curve of HCPT-loaded nanoparticles was
described.
Pharmacokinetic study of HCPT-loaded nanoparticles in 
rabbit plasma
Six New Zealand rabbits were randomized into two
groups. After 12 hours of fasting, a bolus of the sample,
equivalent to 12 mg/kg of HCPT or HCPT-loaded nano-
particles, was injected intravenously into each rabbit.
Blood samples were withdrawn from the aural vein at the
indicated time intervals. After centrifugation, the plasma
supernatant was added to acetic acid (pH 3) to produce
the lactone form of HCPT. Then, cold methanol-ace-
tonitrile (1 : 1, v/v) was used to precipitate proteins. After
centrifuging at 10,000 r/min for 5 min at 4°C, 50 µL of the
supernatant were injected into the high-performance liq-
uid chromatograph (HPLC, HP1100; Agilent) to deter-
mine the lactone concentration. The analytical column
used was Hypersil C18 (5 µm, ID 4.6 mm × 300 mm). The
mobile phase was 0.075 mol/L ammonium acetate buffer
(pH 6.4)/acetonitrile (78:22 [v : v]). The column was
eluted at a flow rate of 1.0 mL/min at room temperature;
and the effluent was monitored spectrofluorometrically
with an excitation wavelength of 269 nm and an emission
wavelength of 550 nm. The concentrations of HCPT were
calculated based on the standard curve, which was set up
using standard HCPT solution, and the pharmacokinetic
parameters of HCPT distribution were estimated using
3p87 programs, or calculated with open two-compart-
ment models.
Tumor inhibition effect of HCPT-loaded nanoparticles in 
vivo
The xenograft model of colon cancer was established sub-
cutaneously in the right flank of BALB/c nude mice. After
xenografts about 5 mm in diameter formed (third day),
the mice were randomly assigned to 4 groups (n = 8) asBMC Biotechnology 2008, 8:46 http://www.biomedcentral.com/1472-6750/8/46
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follows: control, PEG-PBLG, HCPT, and HCPT/PEG-
PBLG. Then HCPT or HCPT/PEG-PBLG, 3 mg/kg, was
intraperitoneally injected daily for 7 times. In the control
group, the same volume of PBS or PEG-PBLG was injected
intraperitoneally. Mice were sacrificed on day 21. Tumor
size was measured by calipers (length and width) every 3
days. The tumor volume (V = 1/2 length × width2) was cal-
culated and the tumor growth curve was generated (y = A
e kt). The tumor doubling time (T = ln2/K, k: growth rate)
and inhibition rate on day 21 were calculated. The inhibi-
tion rate was calculated as follows: (1-the volume change
of experiment group/the volume change of control group)
× 100%. The establishment, grouping, and treatment pro-
tocol of the Tca8113 cell xenograft (oral squamous cell
carcinoma) was similar to the Lovo cell xenograft, except
for the following differences: 1) treatment began on day 8,
2) the drug was injected every 2 days for 8 times (16 days),
and 3) the mice were sacrificed on day 34. The anti-tumor
activity was evaluated as described above.
Statistical analysis
In all cases, experiments were replicated in triplicate and
data represent mean ± s.d. (standard deviation). Statistical
analysis of the inhibitory effect on tumor growth was per-
formed using one-way analysis of variance. P  < 0.05
denoted significance in all cases.
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N,N-dimethylformamide; t1/2: elimination half-life; Cmax:
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